Daniel J. Drucker, MD

Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital

Dr. Drucker received his MD from the University of Toronto in 1980, and is currently Professor of Medicine and the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology at the University of Toronto, and a Senior Scientist at the Lunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital. His laboratory studies the molecular biology and physiology of gut hormones with a focus on the glucagon-like peptides. Dr. Drucker and colleagues were the first to publish that GLP-1(7-37) directly augments glucose-dependent insulin biosynthesis and secretion from β cells, creating a foundation for decades of research in the diabetes and obesity field. His work has revolutionized pharmaceutical developments that have offered enormous benefits for diabetes, obesity and short bowel syndrome.

Glucagon-like peptide-1 exerts peripheral and central actions that control metabolic pathways, appetite, body weight and glucose homeostasis. GLP-1 exerts its actions through a canonical receptor widely expressed in the islets, central and peripheral nervous system and in the heart. Notably, GLP-1R agonists approved for the treatment of diabetes have demonstrated cardiovascular safety, and in some instances, reduced cardiovascular death in outcome studies. This keynote will discuss relevant sites and mechanisms of GLP-1 action, with clinical implications for the treatment of metabolic disease.


9:45am GLP-1: Central and Peripheral Pathways With Cardiovascular Complexity
Daniel J Drucker, MD